Ovarian Cancer – Opportunity Analysis and Forecasts to 2028

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Ovarian Cancer: Executive Summary

2.1 Double-Digit Growth Rate Expected for Ovarian Cancer Between 2018–2028

2.2 Drug Developers Expand Labels Through Novel Combinations and Broadening of Patient Eligibility

2.3 Unmet Need for More Effective Therapies in the Treatment-Resistant Disease Setting Will Largely Remain Unaddressed

2.4 An Individualized Treatment Paradigm Emerges for the First-Line Setting, While Targeted Therapies Are Struggling to Deliver for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors

5.3 Global and Historical Trends

5.3.1 7MM Trends in Diagnosed Incidence

5.3.2 7MM Trends in Observed Survival

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for Ovarian Cancer (2018–2028)

5.5.1 Diagnosed Incident Cases of Ovarian Cancer

5.5.2 Age-Specific Diagnosed Incidence of Ovarian Cancer

5.5.3 Five-Year Diagnosed Prevalent Cases of Ovarian Cancer

5.5.4 Diagnosed Incident Cases of Ovarian Cancer by Stage at Diagnosis

5.5.5 Diagnosed Incident Cases of Cancer of the Ovary (C56) by Histologic Subtype

5.5.6 Diagnosed Incident Cases of Ovarian Cancer with an Associated Germline BRCA Mutation

5.5.7 Diagnosed Incident Cases of Ovarian Cancer with an Associated Somatic BRCA Mutation

5.5.8 Diagnosed Incident Cases of Ovarian Cancer with HRD

5.5.9 Diagnosed Incident Cases of EOC with FRα Overexpression

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Improved Front-Line Therapies

7.3 Alternative Treatment Options for Platinum-Refractory/Resistant Patients

7.4 Individualized Treatment Approaches

7.5 Therapy Option for Histological Subtypes Beyond High-Grade Serous Ovarian Cancer

7.6 An Early-Stage Diagnostic for Ovarian Cancer

8 R&D Strategies

8.1 Overview

8.1.1 PARP Inhibitors Are Becoming a Focus of Clinical Development

8.1.2 Development of Companion Diagnostic and Robust Biomarker Platforms

8.1.3 Novel Mechanism of Action: Folate Receptor Alpha Targeting

8.1.4 Cell-Based Therapies at the Early Stages of Clinical Development

8.1.5 Platinum-Refractory Disease: Patients Might Have to Wait for Breakthrough Therapies

8.2 Clinical Trial Design

8.2.1 Current Clinical Trial Endpoints

8.2.2 Future Clinical Trial Endpoints

8.2.3 Moving Beyond the Current Platinum-Sensitive/Resistant Paradigm for Patient Recruitment in Clinical Trials

9 Pipeline Assessment

9.1 Overview

9.2 Innovative Early-Stage Approaches

9.3 Other Drugs in Development

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Drugs

10.2 Commercial Benchmark of Key Pipeline Drugs

10.3 Competitive Assessment

10.4 Top-Line 10-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Japan

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.3.1 Forecasting Methodology

11.3.2 Diagnosed Patients

11.3.3 Percent Drug-Treated Patients

11.3.4 Drugs Included in Each Therapeutic Class

11.3.5 Launch and Patent Expiry Dates

11.3.6 General Pricing Assumptions

11.3.7 Individual Drug Assumptions

11.3.8 Generic Erosion

11.3.9 Pricing of Pipeline Agents

11.4 Primary Research – KOLs Interviewed for This Report

11.5 Primary Research – Prescriber Survey

11.6 About the Authors

11.6.1 Analyst

11.6.2 Therapy Area Directors

11.6.3 Epidemiologist

11.6.4 Managing Epidemiologist

11.6.5 Global Director of Therapy Analysis and Epidemiology

11.6.6 Global Head and EVP of Healthcare Operations and Strategy

11.7 About GlobalData

11.8 Contact Us

11.9 Disclaimer

Table 1: Ovarian Cancer: Key Metrics in the 7MM

Table 2: FIGO Guidelines: Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum

Table 3: Risk Factors for Ovarian Cancer

Table 4: Treatment Guidelines for Ovarian Cancer, 2019

Table 5: Leading Treatments for Ovarian Cancer, 2019

Table 6: Potential Classification Systems for Recurrent Ovarian Cancer

Table 7: Comparison of Therapeutic Classes in Development for Ovarian Cancer, 2018–2028

Table 8: Innovative Early-Stage Approaches for Ovarian Cancer, 2019

Table 9: Other Drugs in Development for Ovarian Cancer, 2019

Table 10: Clinical Benchmark of Key Pipeline Immuno-oncology Drugs – Ovarian Cancer

Table 11: Clinical Benchmark of Key Pipeline Targeted Therapy Drugs – Ovarian Cancer

Table 12: Commercial Benchmark of Key Pipeline Immuno-oncology Drugs – Ovarian Cancer

Table 13: Commercial Benchmark of Key Pipeline Targeted Therapy Drugs – Ovarian Cancer

Table 14: Key Events Impacting Sales for Ovarian Cancer, 2018–2028

Table 15: Ovarian Cancer Market – Global Drivers and Barriers, 2018–2028

Table 16: Ovarian Cancer US Market – Drivers and Barriers, 2018–2028

Table 17: Ovarian Cancer 5EU Market – Drivers and Barriers, 2018–2028

Table 18: Ovarian Cancer Japan Market – Drivers and Barriers, 2018–2028

Table 19: Key Historical and Projected Launch Dates for Ovarian Cancer

Table 20: Key Historical and Projected Patent Expiry Dates for Ovarian Cancer

Table 21: Average Body BSA Across the 7MM

Table 22: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global Sales Forecast by Country for Ovarian Cancer in 2018 and 2028

Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Avastin in Combination with Paclitaxel + Carboplatin

Figure 3: Diagnosed Incidence of Ovarian Cancer, 7MM, Women, Ages ≥18 Years, 2008–2028, Cases per 100,000 Population

Figure 4: Sources Used and Not Used for Diagnosed Incident Cases of Ovarian Cancer

Figure 5: Sources Used for Diagnosed Incident Cases of Ovarian Cancer by Stage at Diagnosis

Figure 6: Sources Used for Diagnosed Incident Cases of Cancer of the Ovary (C56) by Histologic Subtype

Figure 7: Sources Used for Diagnosed Incident Cases of Ovarian Cancer with an Associated Germline BRCA Mutation

Figure 8: Sources Used for Diagnosed Incident Cases of Ovarian Cancer with an Associated Somatic BRCA Mutation

Figure 9: Sources Used for Diagnosed Incident Cases of Ovarian Cancer with HRD

Figure 10: Sources Used for EOC Cases with FRα Overexpression

Figure 11: Diagnosed Incident Cases of Ovarian Cancer, 7MM, Women, Ages ≥18 Years, 2018

Figure 12: Age-Specific Diagnosed Incident Cases of Ovarian Cancer, 7MM, Women, Ages ≥18 Years, 2018

Figure 13: Five-Year Diagnosed Prevalent Cases of Ovarian Cancer, 7MM, Women, Ages ≥18 Years, 2018, N

Figure 14: Diagnosed Incident Cases of Ovarian Cancer by Stage at Diagnosis, 7MM, Women, Ages ≥18 Years, 2018, N

Figure 15: Diagnosed Incident Cases of Cancer of the Ovary (C56) by Histologic Subtype, 7MM, Women, Ages ≥18 Years, 2018, N

Figure 16: Diagnosed Incident Cases of Ovarian Cancer with an Associated Germline BRCA Mutation, 7MM, Women, Ages ≥18 Years, 2018, N

Figure 17: Diagnosed Incident Cases of Ovarian Cancer with an Associated Somatic BRCA Mutation, 7MM, Women, Ages ≥18 Years, 2018, N

Figure 18: Diagnosed Incident Cases of Ovarian Cancer with HRD, 7MM, Women, Ages ≥18 Years, 2018, N

Figure 19: Diagnosed Incident Cases of EOC with FRα Overexpression, 7MM, Women, Ages ≥18 Years, 2018, N

Figure 20: Top-Level Treatment Flow Chart for Ovarian Cancer Patients

Figure 21: Unmet Needs and Opportunities in Ovarian Cancer

Figure 22: Overview of the Development Pipeline in Ovarian Cancer

Figure 23: Key Phase II/III Trials for IO Agents in Ovarian Cancer Pipeline in the 7MM, 2019

Figure 24: Key Phase II/III Trials for Targeted Therapy Agents in Ovarian Cancer Pipeline in the 7MM, 2019

Figure 25: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Avastin + Chemotherapy

Figure 26: Global (7MM) Sales Forecast by Country for Ovarian Cancer in 2018 and 2028

Figure 27: Global Sales Forecast by Class for Ovarian Cancer in 2018 and 2028

Figure 28: Sales Forecast by Class for Ovarian Cancer in the US in 2018 and 2028

Figure 29: Sales Forecast by Class for Ovarian Cancer in the 5EU in 2018 and 2028

Figure 30: Sales Forecast by Class for Ovarian Cancer in Japan in 2018 and 2028